Global Periodontal Disease Therapeutics Market US$ 173 Million by 2021

Global Periodontal Disease Therapeutics Market US$ 173 Million by 2021

The global periodontal disease therapeutics market is estimated to reach $175 Million in 2021, growing at a CAGR of 8.2% from 2017 to 2021, primarily due to aging population, lack of public awareness, and increased use of tobacco-related products.

Periodontal Disease CDC U.S. Statistics

Data from the Centers for Disease Control and Prevention show high prevalence of periodontal disease in the U.S. population; American Academy of Periodontology encourages yearly comprehensive periodontal evaluations to assess for disease. A recent Centers for Disease Control and Prevention (CDC) report provides the following data related to prevalence of periodontitis in the U.S.: 47.2% of adults aged 30 years and older have some form of periodontal disease, and periodontal Disease increases with age, 70.1% of adults 65 years and older have periodontal disease. This condition is more common in men than women (56.4% vs 38.4%), those living below the federal poverty level (65.4%), those with less than a high school education (66.9%), and current smokers (64.2%).

Periodontal disease and tooth decay are the two biggest threats to dental health. Periodontal diseases are mainly the results of infections and inflammation of the gums and bone that surround and support the teeth. There are a number of types of periodontal disease and they all affect the tissues supporting the teeth. In its early stage, called gingivitis, whereas in its more serious form, called periodontitis. Periodontal disease is mostly seen in adults.

Antibiotic treatments can be used either in combination with surgery and other therapies, or alone, to reduce or temporarily eliminate the bacteria associated with gum disease or suppress the destruction of the tooth’s attachment to the bone. Chlorhexidine (marketed as the prescription-only brands Peridex, PerioChip, PerioGard, and by numerous other over-the-counter trade names) is an antimicrobial used to control plaque and gingivitis in the mouth or in periodontal pockets. The medication is available as a mouth rinse or as a gelatin-filled chip that is placed in pockets after root planing and releases the medication slowly over few days. Other antibiotics, including doxycycline, tetracycline, and minocycline may also be used to treat gum disease. In addition, a nonprescription toothpaste that contains fluoride and an antibiotic to reduce plaque and gingivitis, called triclosan, is often recommended. Scaling and root planing is sometimes followed by adjunctive therapy such as local delivery antimicrobials, systemic antibiotics, and host modulation, as needed on a case-by-case basis.  The antimicrobials include metronidazole in an ointment form (Elyzol), chlorhexidine (Periochip) as well as doxycycline either in a fiber form (Actisite), or also in a polymeric delivery system (Atridox).

The global periodontal disease therapeutics market report provides market size (Revenue US$ Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).

The global periodontal disease therapeutics market segmentation is based on drug types (Arestin, Atridox, Doxycycline, Metronidazole, Minocycline, PerioChip). The global periodontal disease therapeutics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global periodontal disease therapeutics market and included in this report are 3M, DenMat Holdings LLC, Dexcel Pharma, Galderma SA, Kaken Pharmaceuticals, and Valeant Pharmaceutical.

  1. Drug Type
    • Arestin
    • Atridox
    • Doxycycline
    • Metronidazole
    • Minocycline
    • PerioChip
  1. Geography (Region, Country)
    • North America (U.S., Canada)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Middle East
    • Rest of the World
  1. Company Profiles
    • 3M
    • DenMat Holdings, LLC
    • Dexcel
    • Galderma S.A.
    • Kaken Pharmaceuticals Co., Ltd
    • Valeant Pharmaceuticals

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/periodontal-disease-therapeutics-market/

2017-11-17T19:03:10+00:00 Categories: Press Releases|